Results 31 to 40 of about 1,067,180 (299)

Effect of abdominal obesity on insulin resistance and the components of the metabolic syndrome: Evidence supporting obesity as the central feature

open access: yes, 2003
Background: Metabolic syndrome includes abdominal obesity, diabetes type 2, hypertension, dyslipidemia, derangements of fibrinolysis, and atherosclerosis. Since abdominal obesity is one of the major components of the insulin resistance syndrome (IRS), an
Ozcan, Rahşan   +11 more
core   +2 more sources

Association between Abdominal Obesity and Cardiovascular Risk Factors in Adults with Normal Body Mass Index: Based on the Sixth Korea National Health and Nutrition Examination Survey

open access: yesJournal of Obesity & Metabolic Syndrome, 2019
Background : Abdominal obesity predisposes individuals to cardiovascular disease, but the data in adults with normal body mass index (BMI) are relatively rare.
Hye Yun Kim   +4 more
doaj   +1 more source

Abdominal obesity exhibits distinct effect on inflammatory and anti-inflammatory proteins in apparently healthy Japanese men

open access: yesCardiovascular Diabetology, 2007
Background Since visceral fat tissue is known to release various inflammatory and anti-inflammatory cytokines, abdominal obesity may play a key role in the inflammation associated with metabolic syndrome (MetS).
Sugita Yoshiro   +3 more
doaj   +1 more source

Generalised and abdominal obesity and risk of diabetes, hypertension and hypertension–diabetes co-morbidity in England [PDF]

open access: yes, 2008
Objectives To look at trends in generalised (body mass index (BMI) ≥30 kg m–2) and abdominal (waist circumference (WC) >102 cm in men, >88 cm in women) obesity among adults between 1993 and 2003, and to evaluate their association with diabetes ...
Hirani, V.   +2 more
core  

Evaluating the effect of γ‐oryzanol on MASLD pathology using a medaka fish model

open access: yesFEBS Open Bio, EarlyView.
This study explores a liver disease called MASLD, which is increasing worldwide and can lead to serious damage. Researchers used medaka fish instead of rodents to test a food compound, γ‐oryzanol. Fish fed this compound had less liver fat and healthier gut bacteria.
Yukako Ito   +7 more
wiley   +1 more source

Computational modeling enables individual assessment of postprandial glucose and insulin responses after bariatric surgery

open access: yesCommunications Medicine
Background Bariatric surgery enhances glucose metabolism, yet the detailed postprandial joint glucose and insulin responses, variability in individual outcomes, and differences in surgical approaches remain poorly understood. Methods We used hierarchical
Onur Poyraz   +6 more
doaj   +1 more source

Prevalence and geographic variation of abdominal obesity in 7- and 9-year-old children in Greece; World Health Organization Childhood Obesity Surveillance Initiative 2010

open access: yesBMC Public Health, 2017
Background In children, abdominal obesity is a better predictor of the presence of cardiovascular risk factors than body mass index (BMI)-defined obesity.
Maria Hassapidou   +8 more
doaj   +1 more source

Obesity: new insight into the anthropometric classification of fat distribution shown by computed tomography [PDF]

open access: yes, 1985
Twenty eight women presenting for routine computed tomography had their waist, hip, and thigh circumferences measured. The ratio of the area of intra-abdominal fat to the area of subcutaneous fat shown in the computed tomogram taken at the umbilical ...
Ashwell, M., Cole, T.J., Dixon, A.K.
core  

BioMed Central Ltd. [PDF]

open access: yes, 2020
Background: Non-communicable diseases (NCDs) are increasing in Kenya, where HIV/AIDS remains a leading cause of death; however, few studies have investigated obesity and hypertension among adults with HIV infection.
Karama, Mohamed   +2 more
core   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

Home - About - Disclaimer - Privacy